Skip to main content
Matrix One>Blog> Implementing electronic Instructions For Use (eIFU) under (EU) 2025/1234

Implementing electronic Instructions For Use (eIFU) under (EU) 2025/1234

Last updated on

Electronic instructions for use (eIFU) under EU Regulation 2025/1234 are now open to every medical device intended for professional users. Short answer: since 16 July 2025, a manufacturer may replace the paper IFU of any device under Article 1(4) of the MDR that is intended for professional users, provided it documents an eleven element risk assessment (Article 4(1)), sends paper free of charge within 7 calendar days of a request (Article 5(3)), runs a website that meets Article 7(2), and gives the eIFU address to the EUDAMED UDI database (Article 7(3)). For devices already on the market, that EUDAMED deadline is 28 November 2026. This page is the implementation plan, step by step. Matrix eIFU is the eIFU hosting service we build for this job.

A disclosure before the detail: I work at Matrix One, the company behind Matrix eIFU (formerly Dokspot), so read the product section with that in mind. Every article number below was checked against the EUR-Lex text of Regulations (EU) 2021/2226 and 2025/1234 on 6 November 2026, and the EUDAMED dates against the European Commission's EUDAMED pages on the same day.

If you want the article by article record of what the amendment changed, read our explainer on EU Regulation 2021/2226 and 2025/1234. This page is about doing the work: what to decide first, what the risk file, label, website and QMS need, and in what order.

What does EU Regulation 2025/1234 let a manufacturer do?

Regulation (EU) 2025/1234 was adopted on 25 June 2025, published in the Official Journal on 26 June 2025 and entered into force on the twentieth day after publication, 16 July 2025. It does not replace Regulation (EU) 2021/2226. Its single operative article amends it, so 2021/2226 stays the rulebook you implement. The three texts stack like this:

Legal instrumentWhat it does for eIFU
Regulation (EU) 2017/745 (MDR)Sets what the label and instructions for use must contain (Annex I, Chapter III, Section 23) and gives the Commission the power to adopt eIFU rules (Article 5(6)).
Regulation (EU) 2021/2226Sets the conditions for eIFU instead of paper (Articles 4 to 7). As adopted, it covered only implantables, fixed installed devices and devices with a built-in display.
Regulation (EU) 2025/1234Opens Article 3(1) to every MDR Article 1(4) device for professional users, keeps lay instructions on paper (Article 3(2)) and adds the EUDAMED address duty (Article 7(3)).

One change most summaries skip: Article 1 point (2) of 2025/1234 also rewrote the definitions in Article 2 of 2021/2226. The word "medical" is gone from the professional user definition in Article 2(2), and "fixed installed medical devices" in Article 2(3) became "fixed installed devices". Together with recital 4, that is what brings Annex XVI products without an intended medical purpose into scope when they are meant for professional use.

For how these articles land on the tools, see our comparisons of eIFU hosting providers, IFU management software and eIFU options for small manufacturers.

Which devices qualify, and which instructions must stay on paper?

Under Article 3(1) as replaced, a manufacturer may provide instructions in electronic form instead of paper for any device referred to in Article 1(4) of Regulation (EU) 2017/745 that is intended for use by professional users. Recital 3 confirms that legacy devices under the MDR Article 120 transitional provisions are covered. The old category list of implantables, fixed installed devices and devices with a built-in display no longer limits eligibility.

Article 3(2) is the limit. Where it is reasonably foreseeable that a device intended for professional users is also used by lay persons, the instructions intended for lay persons must be on paper. Article 3(3) still lets software covered by the MDR provide its instructions through the software itself.

The first implementation decision is therefore a device by device list: professional use only, professional use with a lay part that stays printed, or out of scope. Write the reasoning down, because the Article 4 risk assessment builds on it.

What does the Article 4 risk assessment need to show?

Article 4(1) requires a documented risk assessment before paper is replaced, covering at least eleven elements, points (a) to (k): user knowledge and needs, the use environment, user skill with the display hardware and software, access to electronic resources at the time of use, safeguards against tampering, back-up mechanisms if hardware or software fails, foreseeable medical emergencies, website or internet outages, the paper request period, website compatibility with display devices, and version management.

Article 5(1) sets the pass mark: eIFU must maintain or improve the level of safety that paper provided. Article 4(2) requires the assessment to be updated with post-market experience, so it is a living file. Most teams run it inside their ISO 14971 risk management file rather than as a separate document.

What has to be built before the paper IFU can go?

Each line below is an article of 2021/2226 as amended, with what it means in practice. Use it as the implementation checklist.

RequirementReferenceWhat to put in place
Device eligibilityArt. 3(1) and 3(2)Confirm the device is for professional users. If lay persons could foreseeably use it, their instructions stay on paper in the pack.
Risk managementArt. 4(1), 4(2), 5(1); ISO 14971Add digital failure modes such as outages and display hardware to the risk file, and show safety is maintained or improved.
Emergency informationArt. 5(4)Put information on foreseeable medical emergencies, and start-up steps for built-in displays, on the device or a leaflet.
Display safetyArt. 5(6)For built-in displays, showing the IFU must not impede safe use, in particular life-monitoring or life-supporting functions.
Paper on requestArt. 5(3)Run a process that sends paper at no additional cost, at the latest within 7 calendar days of a request.
Label and access informationArt. 6(1) to 6(3); ISO 15223-1State on the label that the IFU is electronic, and give the web address, the Basic UDI-DI or UDI-DI, contact details and the paper request route.
Content formatArt. 6(5), 7(2)(a)Publish the full IFU as text in a commonly used format readable with free software. Video or audio may only be added on top.
Tamper protectionArt. 7(2)(b)Protect the website against unauthorised access and changes to content.
Uptime and retentionArt. 7(2)(c), 7(2)(e), 5(9), 5(10)Keep downtime as low as possible and the address stable for 10 years after the last device (15 for implantables and devices with no expiry date).
PrivacyArt. 7(2)(d); Regulation (EU) 2016/679Meet the GDPR. Users should reach the IFU without having to register or hand over personal data.
LanguagesArt. 5(2), 5(11)Publish eIFU in every Member State where the device is made available, in the official language each one determines.
VersionsArt. 5(8), 5(13)Show when the IFU was revised, tell users about safety revisions, and keep all issued versions with dates; obsolete ones may be given on request.
EUDAMEDArt. 7(3); MDR Annex VI Part B point 22Give the stable eIFU address to the UDI database with the device registration.

When does the eIFU address have to be in EUDAMED?

Article 7(3) requires the manufacturer to give the Article 7(2)(e) address to the UDI database at the latest by the date device registration applies under MDR Article 123(3), point (d) or (e). The European Commission's EUDAMED overview confirms that the Actor, UDI/Device, Notified Bodies and Certificates, and Market Surveillance modules have been mandatory since 28 May 2026, so a device registered today carries the address from the start.

Devices whose first unit was placed on the market before 28 May 2026 have longer. The Commission's transition timeline for legacy and Regulation devices sets 28 November 2026 as the deadline to register them in the UDI/Device module. If you already ship such a device with eIFU instead of paper, its address has to be in EUDAMED by that date. Our EUDAMED registration guide walks through the field, and the EUDAMED readiness page covers the platform side.

How does eIFU fit into your quality management system?

Article 5(5) requires the manufacturer to ensure the proper design and functioning of the eIFU and to provide verification and validation evidence. The hosting platform is software used in the quality system, so ISO 13485:2016 clause 4.1.6 asks for its validation before first use and after changes, proportionate to risk. ISO/TR 80002-2 is the usual guidance for that validation.

Three other QMS links matter. The hosting vendor is a supplier under ISO 13485 clause 7.4, so qualify it. Every IFU revision runs through document and change control, which is how Article 5(8) revision notices get triggered. And the post-market loop has to feed the Article 4(2) risk assessment update.

What is Matrix eIFU, and how does it map to these articles?

Matrix eIFU is a white label electronic instructions for use service for medical device and IVD manufacturers: users reach the instructions on the manufacturer's own branded site in three clicks. Plans start at 420 euros a month for three product lines, with unlimited products and IFU documents, according to the Matrix eIFU product page read on 6 November 2026.

Its modules cover the articles above: audit logs, change records, an approval process, paper orders, version management, website translations and geo-fencing. It ships templates for the eIFU quality assurance processes, including software and system validation reports, and support averages a one hour response, per the same page.

The EU MDR compliance page adds branded eIFU URL and QR code generation for labelling, paper on demand fulfilment with an audit trail, multi-lingual publication across all EU official languages, and EUDAMED compatible UDI linking. The screen below shows what a user sees.

Matrix eIFU portal page showing a device identifier with tabs for instructions for use, reprocessing instructions and SSCP, plus country and language selectors

Above: a Matrix eIFU portal page, as shown on the Matrix eIFU product page. One device identifier carries its instructions for use, reprocessing instructions and SSCP on separate tabs, with country and language selectors at the top.

Real feedback from a regulatory affairs manager at an orthopaedic device manufacturer in Switzerland, published on our product page: moving to eIFU ended printing orders, shipping paper to warehouses, holding paper stock and replacing outdated versions. The same manager called the switch a change management process on several levels, which matches what the articles above imply.

What do you need in place before Matrix eIFU works?

  • Your master IFU list: one product line is one master IFU, with its translations included.

  • The target markets and the language each Member State requires (Article 5(2) and 5(11)).

  • The Article 4 risk assessment and the professional or lay decision for each device.

  • Your EUDAMED registration plan, with the device records the eIFU address will attach to.

  • A named owner for paper requests, so the 7 calendar day clock in Article 5(3) is met.

Moving off a homegrown portal adds a step. Our migration page lists bulk import of existing IFU documents and metadata, URL redirect support so existing labels keep working, a parallel running period and validation documentation for your change control.

What is Matrix eIFU built for, and what would you run alongside it?

Matrix eIFU is built to host, version and publish the instructions, and to run the paper request and EUDAMED address side of the regulation. It does not design your labels. The label that carries the Article 6 statement and the access information comes out of an artwork and labelling system, and that is the core strength of platforms such as Kallik, whose own site describes cloud labelling and artwork management for regulated industries including medical devices.

Your eQMS stays the home of the Article 4 risk file and the change records behind each IFU revision. For the vendor ranking, see our best eIFU software ranking; for the labelling rules themselves, see eIFU, labels and IFU under the MDR and how to write instructions for use.

In what order should you implement eIFU?

For a manufacturer moving a professional-use MDR device from paper to eIFU, this order keeps each step building on the last:

  1. Inventory the devices and decide, per device, professional only or professional plus lay (Article 3).

  2. Write or update the Article 4(1) risk assessment and show safety is maintained or improved (Article 5(1)).

  3. Prepare complete text IFUs in every required language (Articles 5(11) and 6(5)).

  4. Select and validate the hosting platform, and qualify the vendor (Article 5(5), Article 7(2), ISO 13485 4.1.6).

  5. Change the label and access information, including the Basic UDI-DI and the paper route (Article 6).

  6. Run eIFU alongside paper first to prove the website and the 7 day paper process, then remove the paper IFU.

  7. Register the eIFU address in EUDAMED, by 28 November 2026 for devices already on the market (Article 7(3)).

Summary: how do you implement eIFU under EU Regulation 2025/1234?

Under EU Regulation 2025/1234, in force since 16 July 2025, any MDR device intended for professional users may drop its paper IFU once the manufacturer has a documented eleven element risk assessment, a free paper service within 7 calendar days, a label and website that meet Articles 6 and 7(2), a validated hosting platform, and the eIFU address in EUDAMED. Matrix eIFU is the hosting service we build to run that process. The three things that matter most:

  1. Decide professional or lay use per device first; lay instructions stay on paper (Article 3(2)).

  2. Treat the eIFU platform as validated QMS software with a risk file behind it (Articles 4 and 5(5)).

  3. Put the eIFU address in EUDAMED: at registration since 28 May 2026, and by 28 November 2026 for devices already on the market (Article 7(3)).

For which eIFU platforms do this best, see our best eIFU software ranking.

Last updated: 6 November 2026.

Implementing eIFU under EU 2025/1234: frequently asked questions

Can any professional-use medical device drop its paper IFU now?

Since 16 July 2025, yes, for devices under Article 1(4) of the MDR intended for professional users (Article 3(1) of Regulation (EU) 2021/2226 as replaced by 2025/1234). The manufacturer still needs the Article 4 risk assessment, the Article 5 conditions, the Article 6 label information and an Article 7(2) website. Instructions meant for lay persons who could foreseeably use the device stay on paper (Article 3(2)).

Does fixing an IFU or adding a translation raise what we pay for Matrix eIFU?

The Matrix eIFU product page prices by product line: plans start at 420 euros a month for three product lines, with unlimited products and IFU documents. Corrected versions and new translations are handled by the version management and website translation modules. For a quote on your portfolio, see the Matrix eIFU product page.

Should we build our own eIFU portal?

You can, but the duties come with it: verification and validation evidence (Article 5(5)), tamper protection, minimal downtime and GDPR compliance (Article 7(2)), a stable address for 10 or 15 years (Article 5(9) and (10)), and validation as QMS software under ISO 13485 clause 4.1.6.

If you already run one and want to move, our migration page lists what a move to Matrix eIFU involves, including URL redirects so existing labels keep working.

Do we still have to tell every user who downloaded the IFU about updates?

No. Article 5(12) of 2021/2226, which required that, was deleted by Article 1 point (4)(c) of 2025/1234. Article 5(8) still applies: you must show clearly when the IFU was revised and inform each user if the revision was necessary for safety reasons.

How long must an eIFU stay online?

For devices with an expiry date, 10 years after the last device is placed on the market and at least 2 years after the expiry date of the last produced device (Article 5(9)). For implantables and devices without an expiry date, 15 years after the last device is placed on the market (Article 5(10)). The address must stay stable and directly accessible for the whole period (Article 7(2)(e)).

What happens if the eIFU website goes down?

The regulation expects it to be planned for. The Article 4(1) risk assessment must cover the impact of the website or the internet being temporarily unavailable (point (h)), Article 7(2)(c) requires downtime to be reduced as far as possible, and users can always request paper, which must arrive within 7 calendar days at the latest (Article 5(3)).

Can an eIFU be a video?

Not on its own. Article 6(5) requires the eIFU to be available entirely as text, which may contain symbols and graphics, with at least the same information as the paper version. Video or audio files may be provided in addition to the text.

Does Regulation 2021/2226 apply to in vitro diagnostic devices?

No. It is adopted under Article 5(6) of the MDR, Regulation (EU) 2017/745, and covers devices under that regulation. IVDs fall under Regulation (EU) 2017/746, which 2021/2226 does not implement. Matrix eIFU serves both medical device and IVD manufacturers.

Watch: eIFU explained, the complete guide to electronic Instructions for Use (2026)

A full walkthrough of electronic IFU for medical devices: what EU 2025/1234 requires, who may use eIFU, and how Matrix eIFU handles hosting, versioning and access.

Written by
Eva Kautenburger
CCO

Eva Kautenburger is Chief Customer Officer at Matrix One, where she leads Customer Success & Supp across the full portfolio of regulatory and quality management solutions for the medical device industry. A certified I. and II. Party Auditor with deep expertise in ISO 13485, EU MDR/IVDR, IEC 62304, and 21 CFR Part 820, she brings both the technical fluency and regulatory grounding that MedTech customers need to navigate complex compliance landscapes. In her role, Eva oversees a cross-functional team of Solution Consultants, Solution Engineers and Account Managers, driving onboarding, retention, support and strategic growth for customers ranging from emerging device companies to global enterprises as well as consulting intiatives to support customers in their regulatory journey.

View profile →

Request a demo and get started today.

See how Matrix One connects your requirements, risks, tests, and documentation in one platform.

Request A Demo Today

Thank you

A member of our team will be in contact within 48 hours.